

■ Bibliografía



- Adams, E; Coomans, D; Smeyers-Verbeke, J; Massart, DL (2002). Non-linear mixed effects models for the evaluation of dissolution profiles. *Int J Pharm*; 240 (1-2): 37-53.
- Adams, E; De Maesschalck, R; De Spiegeleer, B; Vander Heyden, Y; Smeyers-Verbeke, J; Massart, DL (2001). Evaluation of dissolution profiles using principal component analysis. *Int J Pharm*; 212 (1): 41-53.
- AES (2007). The substitution of different formulations of antiepileptic drugs for the treatment of epilepsy (available at <http://www.aesnet.org/77B16A48-E7FF-0F41-218E9CB3E54919D4>).
- Amidon, GL; Lennernas, H; Shah, VP; Crison, JR (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res*; 12 (3): 413-20.
- Andermann, F; Duh, MS; Gosselin, A; Paradis, PE (2007). Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. *Epilepsia*; 48 (3): 464-9.
- Anderson, GD (2008). Understanding the ramifications of switching among AEDS: what are the data? *Adv Stud Med*; 8 (7): 229-234.
- Anderson, NH; Bauer, M; Boussac, N; Khan-Malek, R; Munden, P; Sardaro, M (1998). An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. *J Pharm Biomed Anal*; 17 (4-5): 811-22.
- Anderson, S; Hauck, WW (1990). Consideration of individual bioequivalence. *J Pharmacokinet Biopharm*; 18 (3): 259-73.
- Anderson, S; Hauck, WW (1996). The transitivity of bioequivalence testing: potential for drift. *Int J Clin Pharmacol Ther*; 34 (9): 369-74.
- ANMAT (1999). Requerimiento de Estudios de Bioequivalencia, Disposición 3185/1999 (available at http://www.anmat.gov.ar/webanmat/Legislacion/Medicamentos/Disposicion_ANMAT_3185-1999.pdf).
- ANMAT (2002). Especialidades Medicinales, Disposición 5318/2002 (available at http://www.anmat.gov.ar/webanmat/Legislacion/Medicamentos/Disposicion_ANMAT_5318-2002.pdf).
- ANMAT (2009). Criterios de Bioexención de Estudios de Bioequivalencia para medicamentos sólidos orales de liberación inmediata, Disposición 758/09 (available at http://www.anmat.gov.ar/webanmat/legislacion/medicamentos/Disposicion_ANMAT_758-2009.pdf).
- ANMAT (2011). Listado de Medicamentos de Alto Riesgo e Inmunosupresores con Resultados Aceptables de Biodisponibilidad y Bioequivalencia, Mayo de 2011 (available at http://www.anmat.gov.ar/listados/Listado_Alto_Riesgo_5-2011.pdf).
- Aps, JK; Martens, LC (2005). Review: The physiology of saliva and transfer of drugs into saliva. *Forensic Sci Int*; 150 (2-3): 119-31.
- Arancibia, A; Pezoa, R; Universidad de Chile. Facultad de Ciencias Químicas y Farmacológicas (1992). Biodisponibilidad de medicamentos : Simposio Internacional I. Universidad de Chile, Facultad de Ciencias Químicas y Farmacéuticas, Departamento de Ciencias y Tecnología Farmacéuticas, Santiago de Chile.

- Argumosa, A; Herranz, JL (2000). [Economic aspects of epilepsy]. *Rev Neurol*; 30 Suppl 1: S154-60.
- Argumosa, A; Herranz, JL (2004). Childhood epilepsy: a critical review of cost of-illness studies. *Epileptic Disord*; 6 (1): 31-40.
- Armijo, JA; Herranz, JL (1998). Fármacos antiepilépticos y anticonvulsivos. In: *Farmacología Humana - J. Flórez Ed. Masson, Barcelona [etc.]*. Pp. 517-541
- Bakke, OM; Carné Cladellas, X; García Alonso, F; Peces-Barba, G (1994). *Ensayos clínicos con medicamentos: fundamentos básicos, metodología y práctica*. Doyma, Barcelona.
- Barrett, JS; Batra, V; Chow, A; Cook, J; Gould, AL; Heller, AH, et al. (2000). PhRMA perspective on population and individual bioequivalence. *J Clin Pharmacol*; 40 (6): 561-70.
- Bartoszynski, R; Powers, JD; Herderick, EE; Pultz, JA (2001). Statistical comparison of dissolution curves. *Pharmacol Res*; 43 (4): 369-87.
- Battino, D; Croci, D; Rossini, A; Messina, S; Mamoli, D; Perucca, E (2003). Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. *Epilepsia*; 44 (7): 923-9.
- Bell, WL; Crawford, IL; Shiu, GK (1993). Reduced bioavailability of moisture-exposed carbamazepine resulting in status epilepticus. *Epilepsia*; 34 (6): 1102-4.
- Benet, LZ (1999). Understanding bioequivalence testing. *Transplantation Proceedings*; 31 (3, Supplement 1): 7S-9S.
- Benet, LZ; Goyan, JE (1995). Bioequivalence and narrow therapeutic index drugs. *Pharmacotherapy*; 15 (4): 433-40.
- Berg, MJ; Gross, RA; Haskins, LS; Zingaro, WM; Tomaszewski, KJ (2008). Generic substitution in the treatment of epilepsy: patient and physician perceptions. *Epilepsy Behav*; 13 (4): 693-9.
- Bergen, DC (2009). Pharmacokinetics of phenytoin: reminders and discoveries. *Epilepsy Curr*; 9 (4): 102-4.
- Bernus, I; Dickinson, RG; Hooper, WD; Eadie, MJ (1996). Dose-dependent metabolism of carbamazepine in humans. *Epilepsy Res*; 24 (3): 163-72.
- Berry, MR; Likar, MD (2007). Statistical assessment of dissolution and drug release profile similarity using a model-dependent approach. *J Pharm Biomed Anal*; 45 (2): 194-200.
- Besag, FM (2000). Is generic prescribing acceptable in epilepsy? *Drug Saf*; 23 (3): 173-82.
- Bialer, M; Midha, KK (2010). Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. *Epilepsia*; 51 (6): 941-50.
- Blanchard, J; Harvey, S; Morgan, WJ (1991). Serum/saliva correlations for theophylline in asthmatics. *J Clin Pharmacol*; 31 (6): 565-70.
- Blanchard, J; Harvey, S; Morgan, WJ (1992). Relationship between serum and saliva theophylline levels in patients with cystic fibrosis. *Ther Drug Monit*; 14 (1): 48-54.
- Bourgeois, BF (2000). Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? *Neurology*; 55 (11 Suppl 3): S11-6.

- Box, GEP; Hunter, WG; Hunter, JS (2005). *Estadística para investigadores: introducción al diseño de experimentos, análisis de datos y construcción de modelos*. Reverté, Barcelona.
- Brodie, MJ (2010). Antiepileptic drug therapy the story so far. *Seizure*; 19 (10): 650-5.
- Burkhardt, RT; Leppik, IE; Blesi, K; Scott, S; Gapany, SR; Cloyd, JC (2004). Lower phenytoin serum levels in persons switched from brand to generic phenytoin. *Neurology*; 63 (8): 1494-6.
- Burnham, KP; Anderson, DR (2004). Multimodel Inference - Understanding AIC and BIC in Model Selection *Sociological Methods & Research*; 33 (2): 261-304.
- Cárcamo, EC (1981). *Cinética de Disolución de Medicamentos*, Santiago, Chile.
- Cardot, JM; Degen, P; Flesch, G; Menge, P; Dieterle, W (1995). Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. *Biopharm Drug Dispos*; 16 (7): 603-14.
- Caspari, C (1895). *A Treatise on Pharmacy*, Lea Bros., Philad., 344.
- Chen, ML; Lesko, LJ (2001). Individual bioequivalence revisited. *Clin Pharmacokinetics*; 40 (10): 701-6.
- Chen, SS; Allen, J; Oxley, J; Richens, A (1982). Comparative bioavailability of phenytoin from generic formulations in the United Kingdom. *Epilepsia*; 23 (2): 149-52.
- Chow, SC; Ki, FY (1997). Statistical comparison between dissolution profiles of drug products. *J Biopharm Stat*; 7 (2): 241-58.
- Chow, SC; Liu, JP (2009). *Design and Analysis of Bioavailability and Bioequivalence Studies*. CRC Press, Boca Raton.
- Christians, U; First, MR; Benet, LZ (2000). Recommendations for bioequivalence testing of cyclosporine generics revisited. *Ther Drug Monit*; 22 (3): 330-45.
- Chroscinska-Krawczyk, M; Jargiello-Baszak, M; Walek, M; Tylus, B; Czuczwar, SJ (2011). Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. *Pharmacol Rep*; 63 (1): 12-8.
- Clarke's analysis of drugs and poisons: in pharmaceuticals, body fluids and post-mortem material (2004). Pharmaceutical Press, London.
- Cohen, Y; Pradeau, D (1998). *Análisis químicos farmacéuticos de medicamentos Uteha*, Noriega Editores, México [etc.].
- Collazo Herrera, MM; Ramos Picos, D; Yañez Vega, R; De la Cruz Pérez, B (2007). Should be the Control of Drug Prices a Responsibility of the National Regulatory Authorities? *Lat Am J Pharm*; 26 (6): 913-923.
- Connors, KA (1981). *Curso de análisis farmacéutico (ensayo del medicamento)*. Reverté, Barcelona.
- Corveleyn, S; Remon, JP (1999). Stability of Freeze-Dried Tablets at Different Relative Humidities. *Drug Development and Industrial Pharmacy*; 25 (9): 1005-1013.
- Costa, P (2001). An alternative method to the evaluation of similarity factor in dissolution testing. *Int J Pharm*; 220 (1-2): 77-83.
- Costa, P; Sousa Lobo, JM (2001). Modeling and comparison of dissolution profiles. *Eur J Pharm Sci*; 13 (2): 123-33.

- Crawford, P; Feely, M; Guberman, A; Kramer, G (2006). Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. *Seizure*; 15 (3): 165-76.
- Crawford, P; Hall, WW; Chappell, B; Collings, J; Stewart, A (1996). Generic prescribing for epilepsy. Is it safe? *Seizure*; 5 (1): 1-5.
- Crowder, MJ (1996). Keep timing the tablets: statistical analysis of pill dissolution rates. *Appl Statist*; 45 (3): 323-334.
- Danhof, M; Breimer, DD (1978). Therapeutic drug monitoring in saliva. *Clin Pharmacokinet*; 3 (1): 39-57.
- Dickinson, RG; Hooper, WD; King, AR; Eadie, MJ (1985). Fallacious results from measuring salivary carbamazepine concentrations. *Ther Drug Monit*; 7 (1): 41-5.
- Diletti, E; Hauschke, D; Steinijans, VW (1992). Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. *Int J Clin Pharmacol Ther Toxicol*; 30 (8): 287-90.
- Dokoumetzidis, A; Macheras, P (2006). A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. *Int J Pharm*; 321 (1-2): 1-11.
- Doménech Berrozpe, J; Martínez Lanao, J; Plá Delfina, JM (1997). *Biofarmacia y farmacocinética*. Vol. 1, *Farmacocinética*. Síntesis, Madrid.
- Drobitch, RK; Svensson, CK (1992). Therapeutic drug monitoring in saliva. An update. *Clin Pharmacokinet*; 23 (5): 365-79.
- Duh, MS; Andermann, F; Paradis, PE; Weiner, J; Manjunath, R; Cremieux, PY (2007). The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. *Dis Manag*; 10 (4): 216-25.
- Eadie, MJ (2001). Therapeutic drug monitoring--antiepileptic drugs. *Br J Clin Pharmacol*; 52 Suppl 1: 11S-20S.
- Eichelbaum, M; Tomson, T; Tybring, G; Bertilsson, L (1985). Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. *Clin Pharmacokinet*; 10 (1): 80-90.
- EMA/CPMP (2001). Note for guidance on the investigation of bioavailability and bioequivalence.
- EMA/CPMP (2002). Note for guidance on good clinical practice (CPMP/ICH/135/95).
- EMA/CPMP (2008). Guideline on the Investigation of Bioequivalence.
- Endrenyi, L; Fritsch, S; Yan, W (1991). C_{max}/AUC is a clearer measure than C_{max} for absorption rates in investigations of bioequivalence. *Int J Clin Pharmacol Ther Toxicol*; 29 (10): 394-9.
- Endrenyi, L; Midha, KK (1998). Individual bioequivalence--has its time come? *European Journal of Pharmaceutical Sciences*; 6 (4): 271-277.
- Epilepsy Foundation of America. Commentary. (1990). *J Epilepsy*; 3: 55-59.
- Fagiolino, P (1990). Monitorización de fármacos en saliva: ventajas e inconvenientes. *Acta Farm Bonaerense*; 9 (1): 3-13.
- Fagiolino, P (1999). Monitorización de fármacos en saliva: aplicaciones biofarmacéuticas, farmacocinéticas y terapéuticas. Comisión Sectorial de Investigación Científica de la Universidad de la República, Montevideo, Uruguay.

- Fagiolino, P; Eiraldi, R; Vázquez, M (1996). Modelo farmacocinético flujo-dependiente. Aplicación clínica a la digoxina. *Acta Farm Bonaerense*; 15 (4): 225-238.
- Fagiolino, P; Galante, G; Cousillas, A; Vila, P; Stareczek, S; Vivero, E, et al. (1988). Niveles salivales de teofilina en la administración de formas farmacéuticas de acción prolongada. Relación de concentraciones saliva/plasma como testigo del perfil de liberación in vivo. *Revista A. E. F. H.*; XII (1): 51-57.
- Fagiolino, P; Vázquez, M; Olano, I; Delfino, A (2006). Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. *J Epilepsy Clin Neurophysiol*; 12 (1): 13-16.
- Faigle, JW; Brechbühler, S; Feldman, KF; Richter, WJ (1976). The biotransformation of carbamazepine. In: *Epileptic seizures -- behaviour - pain*. W. Birkmayer Ed. Hans Huber Publishers, Bern/Stuttgart/Viena. Pp. 127 - 140
- Farmacopea Argentina 7ª Edición (2003). Buenos Aires, Argentina.
- FDA (2004). Food and Drug Administration - Savings From Generic Drugs Purchased at Retail Pharmacies.
- FDA (2010). Food and Drug Administration. Food & Drug Administration, Generic Drugs: Questions and Answers.
- FDA/CDER (1992). Statistical Procedures for Bioequivalence Studies using a Standard Two Treatment Cross-over Design.
- FDA/CDER (1997). Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms.
- FDA/CDER (1997b). Guidance for Industry: Extended release oral dosage forms - Development, evaluation, and application of In Vitro/In Vivo correlations.
- FDA/CDER (1997c). Guidance for Industry: Modified release solid oral dosage forms - Scale-Up and Postapproval changes: chemistry, manufacturing, and controls; In Vitro dissolution testing and In Vivo bioequivalence documentation.
- FDA/CDER (2000). Guidance for Industry: Analytical procedures and methods validation (available at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM122858.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM122858.pdf)).
- FDA/CDER (2000). Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
- FDA/CDER (2001). Guidance for Industry: Statistical approaches to establishing Bioequivalence.
- FDA/CDER (2003). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations.
- Fischer, MA; Avorn, J (2003). Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. *Health Serv Res*; 38 (4): 1051-63.
- Florey, K (1988). Analytical profiles of drug substances. Academic Press, San Diego [etc.].
- Fluehler, H; Grieve, AP; Mandallaz, D; Mau, J; Moser, HA (1983). Bayesian approach to bioequivalence assessment: an example. *J Pharm Sci*; 72 (10): 1178-81.

- Fluehler, H; Hirtz, J; Moser, HA (1981). An aid to decision-making in bioequivalence assessment. *J Pharmacokinet Biopharm*; 9 (2): 235-43.
- Friedman, H; Greenblatt, DJ; Burstein, ES; Harmatz, JS; Shader, RI (1986). Population study of triazolam pharmacokinetics. *Br J Clin Pharmacol*; 22 (6): 639-42.
- Ganther, JM; Kreling, DH (2000). Consumer perceptions of risk and required cost savings for generic prescription drugs. *J Am Pharm Assoc (Wash)*; 40 (3): 378-83.
- García, AG; Gandía, L (2001). El ensayo clínico en España. *Farmaindustria*, Madrid.
- García, ME; García Morales, I; Gil-Nagel, A (2008). ¿Cuáles son las consecuencias de la sustitución por fármacos antiepilépticos genéricos? Revisión de la literatura. *Neurol Supl*; 4 (1): 29-34.
- Garg, SK; Kumar, N; Bhargava, VK; Prabhakar, SK (1998). Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. *Clin Pharmacol Ther*; 64 (3): 286-8.
- Giarovich, SS (2001). Genéricos, similares y el problema de la intercambiabilidad. *Rev SAFYBI*; 40 (101): 3-33.
- Giessmann, T; May, K; Modess, C; Wegner, D; Hecker, U; Zschiesche, M, et al. (2004). Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. *Clin Pharmacol Ther*; 76 (3): 192-200.
- Gilman, JT; Alvarez, LA; Duchowny, M (1993). Carbamazepine toxicity resulting from generic substitution. *Neurology*; 43 (12): 2696-7.
- Glende, M; Huller, H; Mai, I; Migulla, H; Prumke, J; Schumann, G (1983). Comparative bioavailability of two carbamazepine tablets. *Int J Clin Pharmacol Ther Toxicol*; 21 (12): 631-3.
- Glynn, JP; Bastain, W (1973). Salivary excretion of paracetamol in man. *J Pharm Pharmacol*; 25 (5): 420-1.
- Goodman, LS; Gilman, A (2006). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. McGraw-Hill, Medical Publishing Division, New York.
- Gosselin, PM; Thibert, R; Preda, M; McMullen, JN (2003). Polymorphic properties of micronized carbamazepine produced by RESS. *International Journal of Pharmaceutics*; 252 (1-2): 225-233.
- Gould, AL (2000). A practical approach for evaluating population and individual bioequivalence. *Stat Med*; 19 (20): 2721-40.
- Graffner, C (2006). Regulatory aspects of drug dissolution from a European perspective. *Eur J Pharm Sci*; 29 (3-4): 288-93.
- Green, JR; Margerison, D (1978). *Statistical treatment of experimental data*. Elsevier Scientific Publishing Company, Amsterdam.
- Greiner-Sosanko, E; Giannoutsos, S; Lower, DR; Virji, MA; Krasowski, MD (2007). Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam. *J Chromatogr Sci*; 45 (9): 616-22.
- Groschl, M; Kohler, H; Topf, HG; Rupprecht, T; Rauh, M (2008). Evaluation of saliva collection devices for the analysis of steroids, peptides and therapeutic drugs. *J Pharm Biomed Anal*; 47 (3): 478-86.

- Groth, U; Prellwitz, W; Jahnchen, E (1974). Estimation of pharmacokinetic parameters of lithium from saliva and urine. *Clin Pharmacol Ther*; 16 (3): 490-8.
- Guyton, AC; Hall, JE (2006). *Fisiologia Medica*. Elsevier, Madrid.
- Haas, JS; Phillips, KA; Gerstenberger, EP; Seger, AC (2005). Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. *Ann Intern Med*; 142 (11): 891-7.
- Haidar, SH; Makhoulouf, F; Schuirmann, DJ; Hyslop, T; Davit, B; Conner, D, et al. (2008). Evaluation of a scaling approach for the bioequivalence of highly variable drugs. *Aaps J*; 10 (3): 450-4.
- Hartley, R; Aleksandrowicz, J; Ng, PC; McLain, B; Browmer, CJ; Forsythe, WI (1990). Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? *Br J Clin Pract*; 44: 270-273.
- Hauck, WW; Anderson, S (1984). A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. *J Pharmacokinet Biopharm*; 12 (1): 83-91.
- Hauck, WW; Anderson, S (1994). Measuring switchability and prescribability: when is average bioequivalence sufficient? *J Pharmacokinet Biopharm*; 22 (6): 551-64.
- Hauschke, D; Steinijans, VW; Diletti, E (1992a). A distribution-free procedure for the statistical analysis of bioequivalence studies. *Int J Clin Pharmacol Ther Toxicol*; 30 Suppl 1: S37-43.
- Hauschke, D; Steinijans, VW; Diletti, E; Burke, M (1992b). Sample size determination for bioequivalence assessment using a multiplicative model. *J Pharmacokinet Biopharm*; 20 (5): 557-61.
- Hauschke, D; Steinijans, VW; Pigeot, I (2007). *Bioequivalence Studies in Drug Development. Methods and Applications*. Wiley, Chichester.
- Haut, SR; Hall, CB; Masur, J; Lipton, RB (2007). Seizure occurrence: precipitants and prediction. *Neurology*; 69 (20): 1905-10.
- Hayashi, Y; Watanabe, J; Iwamoto, K; Ozeki, S (1988). Salivary excretion of 5-fluorouracil. II. Fluctuation of saliva/plasma concentration ratio and salivary clearance during a constant rate intravenous infusion in beagle dogs. *J Pharmacobiodyn*; 11 (6): 438-43.
- Heim, M; Bruguierolle, B; Bouvenot, G; Valli, M; Jadot, G; Simonin, R (1980). [Value of the analysis of salivary theophylline with an immunoenzymatic method]. *Therapie*; 35 (2): 251-3.
- Henney, JE (1999). From de Food and Drug Administration: Review of Generic Bioequivalence Studies. *JAMA*; 282 (21): 1995.
- Hodges, S; Forsythe, WI; Gillies, D; Remington, H; Cawood, A (1986). Bio-availability and dissolution of three phenytoin preparations for children. *Dev Med Child Neurol*; 28 (6): 708-12.
- Hofman, LF (2001). Human saliva as a diagnostic specimen. *J Nutr*; 131 (5): 1621S-5S.
- Hold, KM; de Boer, D; Soedirman, JR; Zuidema, J; Maes, RA (1995). The secretion of propranolol enantiomers in human saliva: evidence for active transport? *J Pharm Biomed Anal*; 13 (11): 1401-7.

- Holder, DJ; Hsuan, F (1993). Moment-based criteria for determining bioequivalence. *Biometrika*; 80: 835-846.
- Horning, MG; Brown, L; Nowlin, J; Lertratanangkoon, K; Kellaway, P; Zion, TE (1977). Use of saliva in therapeutic drug monitoring. *Clin Chem*; 23 (2 PT. 1): 157-64.
- Hotelling, H (1931). The generalization of Student's ratio. *Annals of Mathematical Statistics*; 2 (3): 360-378.
- Houssay, BA; Cingolani, HE; Houssay, AB (1988). *Fisiología humana de Bernardo A. Houssay - Tomo I. El Ateneo, Buenos Aires.*
- How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry. (1998). US Government Printing Office, Washington, DC.
- Hundt, HK; Aucamp, AK; Muller, FO; Potgieter, MA (1983). Carbamazepine and its major metabolites in plasma: a summary of eight years of therapeutic drug monitoring. *Ther Drug Monit*; 5 (4): 427-35.
- Infostat, Manual del usuario (2011). Córdoba, Argentina.
- Jackson, AJ (1994). *Generics and bioequivalence*. CRC Press, Boca Raton.
- Jacobson, ED (1981). Salivary secretion. In: *Gastrointestinal physiology*. L. R. Johnson Ed. C. V. Mosby, St. Louis, Missouri. Pp. 46-54
- Jain, KK (1993). Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. *J R Soc Med*; 86 (3): 133-6.
- Johannessen, SI; Landmark, CJ (2010). Antiepileptic drug interactions - principles and clinical implications. *Curr Neuropharmacol*; 8 (3): 254-67.
- Jonkman, JH; Koeter, GH; Schoemaker, R; de Vries, K; Greving, JE; de Zeeuw, RA (1981). Correlation of serum and saliva theophylline concentration after administration of a sustained release preparation. *Eur J Clin Pharmacol*; 20 (1): 73-8.
- Joukhadar, C; Schenk, B; Kaehler, ST; Kollenz, CJ; Bauer, P; Muller, M, et al. (2003). A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations. *Eur J Clin Pharmacol*; 59 (8-9): 631-6.
- Jung, H; Milán, RC; Girard, ME; León, F; Montoya, MA (1997). Bioequivalence study of carbamazepine tablets: in vitro/in vivo correlation. *Int J Pharm*; 152 (1): 37-44.
- Kaufman, E; Lamster, IB (2002). The diagnostic applications of saliva--a review. *Crit Rev Oral Biol Med*; 13 (2): 197-212.
- Kees de Joncheere, A; Rietveld, H; Huttin, C (2003). Experiences with generics. In: *Drugs and Money. Prices, Affordability and Cost Containment*. M. N. G. Dukes, F. M. Haaijer-Ruskamp, C. P. de Joncheere and A. H. Rietveld Ed. World Health Organization, Gêneva. Pp.
- Keitel, S (2011). El papel de la farmacoepia en un mundo globalizado. *Pharmaceutical Technology Sudamérica*; 110: 54-56.
- Kimani, EK; Potvin, D (1997). A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence. *J Pharmacokinet Biopharm*; 25 (5): 595-614.

- Knop, HJ; Kalafusz, R; Knols, AJF; van der Kleijn, E (1975). Preliminary report of the saliva/plasma ratio of theophylline after the administration of theophylline derivatives in suppositories. *Pharm Weekblad*; 110: 1297-1299.
- Knott, C; Bateman, M; Reynolds, F (1984). Do saliva concentrations predict plasma unbound theophylline concentrations? A problem re-examined. *Br J Clin Pharmacol*; 17 (1): 9-14.
- Koch, G; Allen, JP (1978). Untoward effects of generic carbamazepine therapy. *Arch Neurol*; 44 (578-579).
- Korinthenberg, R; Burkart, P; Woelfle, C; Moenting, JS; Ernst, JP (2007). Pharmacology, efficacy, and tolerability of potassium bromide in childhood epilepsy. *J Child Neurol*; 22 (4): 414-8.
- Kortejarvi, H; Yliperttula, M; Dressman, JB; Junginger, HE; Midha, KK; Shah, VP, et al. (2005). Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. *J Pharm Sci*; 94 (8): 1617-25.
- Koup, JR; Jusko, WJ; Goldfarb, AL (1975). pH-dependent secretion of procainamide into saliva. *J Pharm Sci*; 64 (12): 2008-10.
- Kovacevic, I; Parojcic, J; Homsek, I; Tubic-Grozdanic, M; Langguth, P (2009). Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. *Mol Pharm*; 6 (1): 40-7.
- Kramer, G; Steinhoff, BJ; Feucht, M; Pfafflin, M; May, TW (2007). Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. *Epilepsia*; 48 (3): 609-11.
- Kwan, P; Brodie, MJ (2004). Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. *Epilepsia*; 45 (9): 1141-9.
- Lake, OA; Olling, M; Barends, DM (1999). In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. *Eur J Pharm Biopharm*; 48 (1): 13-9.
- Lam, G; Chiou, WL (1982). Determination of the steady-state volume of distribution using arterial and venous plasma data from constant infusion studies with procainamide. *J Pharm Pharmacol*; 34 (2): 132-4.
- Lee, TC; Charles, BG; Steer, PA; Flenady, VJ (1996). Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. *Ther Drug Monit*; 18 (3): 288-93.
- Levy, G; Hayes, BA (1960). Physicochemical basis of the buffered acetylsalicylic acid controversy. *N Engl J Med*; 262: 1053-8.
- Liao, JJ (2007). A new approach for outliers in a bioavailability/bioequivalence study. *J Biopharm Stat*; 17 (3): 393-405.
- Lindenberg, M; Kopp, S; Dressman, JB (2004). Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. *Eur J Pharm Biopharm*; 58 (2): 265-78.
- Liow, K; Barkley, GL; Pollard, JR; Harden, CL; Bazil, CW (2007). Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. *Neurology*; 68 (16): 1249-50.

- Locke, CS (1984). An exact confidence interval from untransformed data for the ratio of two formulation means. *J Pharmacokinet Biopharm*; 12 (6): 649-55.
- Lowe, JR; Dixon, JS (1983). Salivary kinetics of prednisolone in man. *J Pharm Pharmacol*; 35 (6): 390-1.
- Lowenthal, DT; Oie, S; Van Stone, JC; Briggs, WA; Levy, G (1976). Pharmacokinetics of acetaminophen elimination by anephric patients. *J Pharmacol Exp Ther*; 196 (3): 570-8.
- MacKichan, JJ; Duffner, PK; Cohen, ME (1981). Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients. *Br J Clin Pharmacol*; 12 (1): 31-7.
- Maldonado, C; Fagiolino, P; Vázquez, M; Eiraldi, R; Alvariza, S; Bentancur, C, et al. (2011). Time-dependent and concentration-dependent upregulation of carbamazepine efflux transporter. A preliminary assessment from salivary drug monitoring. *Lat Am J Pharm*; 30 (5): 908-912.
- Mandallaz, D; Mau, J (1981). Comparison of different methods for decision-making in bioavailability assessment. *Biometrics*; 37 (2): 213-222.
- Mauger, JW; Chilko, D; Howard, S (1986). On the Analysis of Dissolution Data. *Drug Dev Ind Pharm*; 12 (7): 969-992.
- Mayer, T; May, TW; Altenmuller, DM; Sandmann, M; Wolf, P (1999). Clinical problems with generic antiepileptic drugs: comparison of sustained-release formulations of carbamazepine. *Clinical Drug Investigation*; 18 (1): 17-26.
- McAuliffe, JJ; Sherwin, AL; Leppik, IE; Fayle, SA; Pippenger, CE (1977). Salivary levels of anticonvulsants: a practical approach to drug monitoring. *Neurology*; 27 (5): 409-13.
- Meffin, PJ; Williams, RL; Blaschke, TF; Rowland, M (1977). Application of salivary concentration data to pharmacokinetic studies with antipyrine. *J Pharm Sci*; 66 (1): 135-7.
- Melikian, AP; Straughn, AB; Slywka, GW; Whyatt, PL; Meyer, MC (1977). Bioavailability of 11 phenytoin products. *J Pharmacokinet Biopharm*; 5 (2): 133-46.
- Mennickent, S; Vega, M; Godoy, CG; Leon, MD (2007). [Saliva and plasma levels of carbamazepine have a poor correlation: a pilot study]. *Rev Med Chil*; 135 (3): 335-40.
- Meredith, P (2003). Bioequivalence and other unresolved issues in generic drug substitution. *Clin Ther*; 25 (11): 2875-2890.
- Meyer, MC; Straughn, AB; Jarvi, EJ; Wood, GC; Pelsor, FR; Shah, VP (1992). The bioequivalence of carbamazepine tablets with a history of clinical failures. *Pharm Res*; 9 (12): 1612-6.
- Meyer, MC; Straughn, AB; Mhatre, RM; Shah, VP; Williams, RL; Lesko, LJ (1998). The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. *Pharm Res*; 15 (11): 1787-91.
- Midha, KK; Rawson, MJ; Hubbard, JW (1998). Bioequivalence: Switchability and scaling. *European Journal of Pharmaceutical Sciences*; 6 (2): 87-91.
- Midha, KK; Rawson, MJ; Hubbard, JW (1999). Prescribability and switchability of highly variable drugs and drug products. *Journal of Controlled Release*; 62 (1-2): 33-40.

- Mikati, M; Bassett, N; Schachter, S (1992). Double-blind randomized study comparing brand-name and generic phenytoin monotherapy; 33 (2): 359-65.
- Miles, MV; Tennison, MB; Greenwood, RS (1991). Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. *Ther Drug Monit*; 13 (2): 166-71.
- Moore, JW; Flanner, HH (1996). Mathematical comparison of dissolution profiles. *Pharm Technol*; 20 (6): 64-75.
- Neuvonen, PJ (1985). Bioavailability and central side effects of different carbamazepine tablets. *Int J Clin Pharmacol Ther Toxicol*; 23 (4): 226-32.
- Noyes, AA; Whitney, WR (1897). The rate of solution of solid substances in their own solutions. *J Am Chem Soc*; 19: 930-934.
- Nuwer, MR; Browne, TR; Dodson, WE; Dreifuss, FE; Engel, J, Jr.; Leppik, IE, et al. (1990). Generic substitutions for antiepileptic drugs. *Neurology*; 40 (11): 1647-51.
- O'Hara, T; Dunne, A; Butler, J; Devane, J (1998). A review of methods used to compare dissolution profile data. *Pharmaceutical Science & Technology Today*; 1 (5): 214-223.
- Olling, M; Mensinga, TT; Barends, DM; Groen, C; Lake, OA; Meulenbelt, J (1999). Bioavailability of carbamazepine from four different products and the occurrence of side effects. *Biopharm Drug Dispos*; 20 (1): 19-28.
- Pabst, G; Jaeger, H (1990). Review of methods and criteria for the evaluation of bioequivalence studies. *Eur J Clin Pharmacol*; 38 (1): 5-10.
- Patel, HI; Gupta, GD (1984). A problem of equivalence in clinical trials. *Biometrical Journal*; 26 (5): 471-474.
- Patterson, S (2001). A review of the development of statistical design and analysis techniques for assessing in vivo bioequivalence: Part two. *Ind J Pharm Sci*; 63 (3): 169-186.
- Paxton, JW; Donald, RA (1980). Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. *Clin Pharmacol Ther*; 28 (5): 695-702.
- Pedersen, SA; Dam, M (1985). [Carbamazepine: are synonymous preparations identical?]. *Ugeskr Laeger*; 147 (34): 2676-7.
- Peeters, K; Adriaenssen, I; Wapenaar, R; Neto, W; Pledger, G (2003). A pooled analysis of adjunctive topiramate in refractory partial epilepsy. *Acta Neurol Scand*; 108 (1): 9-15.
- Pilchik, R (2000). Pharmaceutical Blister Packaging, Part I: Rationale and Materials. *Pharm Technol*; 24 (11): 68-78.
- Plavsic, F; Culig, J; Bakran, I, Jr.; Vrhovac, B (1981). Theophylline concentration in saliva as a guide for individualization of its therapeutic use. *Br J Clin Pharmacol*; 11 (5): 533-4.
- Polli, JE; Rekhi, GS; Shah, VP (1996). Methods to compare dissolution profiles. *Drug Inf J*; 30: 1113-1120.
- Polli, JE; Singh Rekhi, G; Augsburg, LL; Shah, VP (1997). Methods to compare dissolution profiles and a rationale for wide dissolution specifications for Metoprolol Tartrate tablets. *Journal of Pharmaceutical Sciences*; 86 (6): 690-700.

- Posti, J (1982). Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. *Pharm Acta Helv*; 57 (3): 83-92.
- Potthast, H; Dressman, JB; Junginger, HE; Midha, KK; Oeser, H; Shah, VP, et al. (2005). Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. *J Pharm Sci*; 94 (10): 2121-31.
- Pynnönen, S (1977). The pharmacokinetics of carbamazepine in plasma and saliva of man. *Acta Pharmacol Toxicol (Copenh)*; 41 (5): 465-71.
- Ramsay, T; Elkum, N (2005). A comparison of four different methods for outlier detection in bioequivalence studies. *J Biopharm Stat*; 15 (1): 43-52.
- Rasmussen, F (1964). Salivary Excretion of Sulphonamides and Barbiturates by Cows and Goats. *Acta Pharmacol Toxicol (Copenh)*; 21: 11-9.
- Rescigno, A (1992). Bioequivalence. *Pharm Res*; 9 (7): 925-8.
- Reunanen, M; Heinonen, EH; Nyman, L; Anttila, M (1992). Comparative bioavailability of carbamazepine from two slow-release preparations. *Epilepsy Res*; 11 (1): 61-6.
- Richens, A (1997). Impact of Generic Substitution of Anticonvulsants on the Treatment of Epilepsy. *CNS Drugs*; 8 (2): 124-133.
- Ritschel, WA (1984). What is bioavailability? Philosophy of bioavailability testing. *Methods Find Exp Clin Pharmacol*; 6 (12): 777-86.
- Ritschel, WA (1987). Aspects for bioavailability and bioequivalence revision: possible implications on clinical pharmacology. *Methods Find Exp Clin Pharmacol*; 9 (7): 453-9.
- Ritschel, WA; Hussain, SA; Schneider, B; Betzien, G; Kaufmann, B (1985). Evaluation of bioavailability by different methods. *Methods Find Exp Clin Pharmacol*; 7 (8): 439-49.
- Ritschel, WA; Tompson, GA (1983). Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure. *Methods Find Exp Clin Pharmacol*; 5 (8): 511-25.
- Rocke, DM (1984). On testing for bioequivalence. *Biometrics*; 40 (1): 225-30.
- Rodda, BE; Davis, RL (1980). Determining the probability of an important difference in bioavailability. *Clin Pharmacol Ther*; 28 (2): 247-52.
- Rosenbaum, DH; Rowan, AJ; Tuchman, L; French, JA (1994). Comparative bioavailability of a generic phenytoin and Dilantin. *Epilepsia*; 35 (3): 656-60.
- Rosenthal, E; Hoffer, E; Ben-Aryeh, H; Badarni, S; Benderly, A; Hemli, Y (1995). Use of saliva in home monitoring of carbamazepine levels; 36 (1): 72-4.
- Russell, WMS; Burch, RL (1959). *The Principles of Humane Experimental Technique*. Available at http://altweb.jhsph.edu/pubs/books/humane_exp/het-toc [last accessed October 2010]. London.
- Rustichelli, C; Gamberini, G; Ferioli, V; Gamberini, MC; Ficarra, R; Tommasini, S (2000). Solid-state study of polymorphic drugs: carbamazepine. *Journal of Pharmaceutical and Biomedical Analysis*; 23 (1): 41-54.
- Rylance, GW; Butcher, GM; Moreland, T (1977). Saliva carbamazepine levels in children. *Br Med J*; 2 (6100): 1481.
- Sachdeo, RC; Belendiuk, G (1987). Generic versus branded carbamazepine. *Lancet*; 1 (8547): 1432.

- Saranadasa, H (2001). Defining similarity of dissolution profiles through Hotteling's T2 statistic. *Pharm Technol*; 25 (2): 46-54.
- Sathe, P; Tsong, Y; Shah, VP (1997). In vitro dissolution profile comparison and IVIVR. Carbamazepine case. *Adv Exp Med Biol*; 423: 31-42.
- Sathe, PM; Tsong, Y; Shah, VP (1996). In-vitro dissolution profile comparison: statistics and analysis, model dependent approach. *Pharm Res*; 13 (12): 1799-803.
- Schall, R (1995). A unified view of individual, population, and average bioequivalence. In: *BIO-International 2. Bioavailability, Bioequivalence and Pharmacokinetic Studies*. H. H. Blume and K. K. Midha Ed. Medpharm Scientific, Stuttgart. Pp. 91-106
- Schall, R; Endrenyi, L (2010). Bioequivalence: tried and tested. *Cardiovasc J Afr*; 21 (2): 69-71.
- Schall, R; Endrenyi, L; Ring, A (2010). Residuals and outliers in replicate design crossover studies. *J Biopharm Stat*; 20 (4): 835-49.
- Schall, R; Luus, HG (1992). Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. *Int J Clin Pharmacol Ther Toxicol*; 30 (5): 153-9.
- Schall, R; Luus, HG (1993). On population and individual bioequivalence. *Stat Med*; 12 (12): 1109-24.
- Schall, R; Williams, RL (1996). Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group. *J Pharmacokinet Biopharm*; 24 (1): 133-49.
- Schuurmann, DJ (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *J Pharmacokinet Biopharm*; 15 (6): 657-80.
- Schumaker, R; Metzler, C (1998). The phenytoin trial is a case study of individual bioequivalence. *Drug Inf J*; 32: 1063-1072.
- Selwyn, MR; Dempster, AP; Hall, NR (1981). A Bayesian approach to bioequivalence for the 2 x 2 changeover design. *Biometrics*; 37 (1): 11-21.
- Selwyn, MR; Hall, NR (1984). On Bayesian methods for bioequivalence. *Biometrics*; 40 (4): 1103-8.
- Shah, VP; Midha, KK; Dighe, S; McGilveray, IJ; Skelly, JP; Yacobi, A, et al. (1991). Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. *Eur J Drug Metab Pharmacokinet*; 16 (4): 249-55.
- Shah, VP; Riegelman, S (1974). GLC determination of theophylline in biological fluids. *J Pharm Sci*; 63 (8): 1283-5.
- Shah, VP; Tsong, Y; Sathe, P; Liu, JP (1998). In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2. *Pharm Res*; 15 (6): 889-96.
- Shah, VP; Yacobi, A; Barr, WH; Benet, LZ; Breimer, D; Dobrinska, MR, et al. (1996). Evaluation of orally administered highly variable drugs and drug formulations. *Pharm Res*; 13 (11): 1590-4.
- Shah, VP; Yamamoto, LA; Schuurman, D; Elkins, J; Skelly, JP (1987). Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets. *Pharm Res*; 4 (5): 416-9.

- Shargel, L; Yu, ABC (1993). Applied biopharmaceutics and pharmacokinetics. Prentice-Hall International, London [etc.].
- Sheiner, LB (1992). Bioequivalence revisited. *Stat Med*; 11 (13): 1777-88.
- Shimada, M; Takahashi, K; Ohkawa, T; Segawa, M; Higurashi, M (1995). Determination of salivary cortisol by ELISA and its application to the assessment of the circadian rhythm in children. *Horm Res*; 44: 213-217.
- Shrank, WH; Hoang, T; Ettner, SL; Glassman, PA; Nair, K; DeLapp, D, et al. (2006). The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. *Arch Intern Med*; 166 (3): 332-7.
- Siegel, IA; Ben-Aryeh, H; Gozal, D; Colin, AA; Szargel, R; Laufer, D (1990). Comparison of unbound and total serum theophylline concentrations with those of stimulated and unstimulated saliva in asthmatic children. *Ther Drug Monit*; 12 (5): 460-4.
- Silpakit, O; Amornpichetkoon, M; Kaojarern, S (1997). Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. *Ann Pharmacother*; 31 (5): 548-52.
- Silva, MdF; Schramm, SG; Kano, EK; Koono, EEM; Porta, V; dos Reis Serra, CH (2010). Bioequivalence evaluation of single doses of two tramadol formulations: A randomized, open-label, two-period: Crossover study in healthy brazilian volunteers. *Clin Ther*; 32 (4): 758-765.
- Smith, M; Whitehead, E; O'Sullivan, G; Reynolds, F (1991). A comparison of serum and saliva paracetamol concentrations. *Br J Clin Pharmacol*; 31 (5): 553-5.
- Spitz, MC (1998). Injuries and death as a consequence of seizures in people with epilepsy. *Epilepsia*; 39 (8): 904-7.
- Steinijans, VW; Diletti, E (1983). Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. *Eur J Clin Pharmacol*; 24 (1): 127-36.
- Steinijans, VW; Eicke, R; Ahrens, J (1982). Pharmacokinetics of theophylline in patients following short-term intravenous infusion. *Eur J Clin Pharmacol*; 22 (5): 417-22.
- Steinijans, VW; Hauschke, D; Jonkman, JH (1992). Controversies in bioequivalence studies. *Clin Pharmacokinet*; 22 (4): 247-53.
- Stephen, KW; McCrossan, J; Mackenzie, D; Macfarlane, CB; Speirs, CF (1980). Factors determining the passage of drugs from blood into saliva. *Br J Clin Pharmacol*; 9 (1): 51-5.
- Suzuki, Y; Cox, S; Hayes, J; Walson, PD (1991). Carbamazepine age-dose ratio relationship in children. *Ther Drug Monit*; 13 (3): 201-8.
- Systat[®] 12 Statistics I_II_III_IV (2007). San Jose, CA.
- The United States Pharmacopeia 31 (2008). United States Pharmacopeia Convention, Rockville, MD.
- Thijssen, JH; Gispens-de Wied, CC; van Heeswijk, GM; Veeman, W (1996). Determination of dexamethasone in saliva. *Clin Chem*; 42 (8 Pt 1): 1238-42.
- Tothfalusi, L; Endrenyi, L; Arieta, AG (2009). Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. *Clin Pharmacokinet*; 48 (11): 725-43.

- Tsang, YC; Pop, R; Gordon, P; Hems, J; Spino, M (1996). High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil. *Pharm Res*; 13 (6): 846-50.
- Tsong, Y; Hammerstrom, T; Sathe, P; Shah, VP (1996). Statistical assessment of mean difference between two dissolution data sets. *Drug Inf J*; 30: 1105-1112.
- Tsume, Y; Amidon, GL (2010). The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. *Mol Pharm*; 7 (4): 1235-43.
- Tubic-Grozdanis, M; Bolger, MB; Langguth, P (2008). Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. *Aaps J*; 10 (1): 213-26.
- Tucker, GT; Boas, RA (1971). Pharmacokinetic aspects of intravenous regional anesthesia. *Anesthesiology*; 34 (6): 538-49.
- Tucker, GT; Mather, LE (1975). Pharmacology of local anaesthetic agents. Pharmacokinetics of local anaesthetic agents. *Br J Anaesth*; 47 suppl: 213-24.
- Uden, DL; Miller, KW; Strand, LM; Johnson, PB; Zaske, DE (1981). Saliva-serum theophylline concentrations: substantial inpatient and outpatient variation in predicting serum concentrations. *Ther Drug Monit*; 3 (2): 143-50.
- US Congressional Budget Office (1998). How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry. US Government Printing Office, Washington, DC.
- Vázquez, M; Fagiolino, P; Rubio, M; Maletta-Fraile, L (1993). Bioequivalence study between two conventional tablets of carbamazepine using saliva as biological fluid. *Eur J Drug Metab Pharmacokinet (Special Issue B)*: 164-8.
- Veng-Pedersen, P; Gobburu, JV; Meyer, MC; Straughn, AB (2000). Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. *Biopharm Drug Dispos*; 21 (1): 1-6.
- Vining, RF; McGinley, RA (1986). Hormones in saliva. *Crit Rev Clin Lab Sci*; 23 (2): 95-146.
- Volonté, MG; Viñas, MA; Buschiazzi, PM; Piersante, MV; Escalles, MC; Gorriti, C (2004). Estudio comparativo de comprimidos con 200 mg de Carbamazepina para determinar Equivalencia Farmacéutica. *Acta Farm Bonarense*; 23 (3): 391-397.
- Wang, JT; Shiu, GK; Ong-Chen, T; Viswanathan, CT; Skelly, JP (1993). Effects of humidity and temperature on in vitro dissolution of carbamazepine tablets. *J Pharm Sci*; 82 (10): 1002-5.
- Wang, W; Chow, SC (2003). Examining outlying subjects and outlying records in bioequivalence trials. *J Biopharm Stat*; 13 (1): 43-56.
- Wang, W; Gene Hwang, JT (2001). A nearly unbiased test for individual bioequivalence problems using probability criteria. *Journal of Statistical Planning and Inference*; 99 (1): 41-58.
- Watson, DG (2005). *Pharmaceutical analysis: a textbook for pharmacy students and pharmaceutical chemists*. Churchill Livingstone, Edinburgh [etc.].
- Welty, TE; Pickering, PR; Hale, BC; Arazi, R (1992). Loss of seizure control associated with generic substitution of carbamazepine. *Ann Pharmacother*; 26 (6): 775-7.

- Westenberg, HG; de Zeeuw, RA; van de Kleijn, E; Oei, TT (1977). Relationship between carbamazepine concentrations in plasma and saliva in man as determined by liquid chromatography. *Clin Chim Acta*; 79 (1): 155-61.
- Westlake, WJ (1972). Use of confidence intervals in analysis of comparative bio-availability trials. *J Pharm Sci*; 61 (8): 1340-1.
- Westlake, WJ (1976). Symmetrical confidence intervals for bioequivalence trials. *Biometrics*; 32 (4): 741-4.
- WHO (2004). World Health Organization. The World medicines situation. Gêneva.
- WHO (2006). Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. 40th Report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series No. 937: 347-390.
- WHO (2010). Pharmaceutical development for multisource (generic) pharmaceutical products.
- Wilches, L; Peláez, C; Barbé, C; Halbaut, L; Aróztegui, M (2003). Re-embasado de medicamentos en dispositivos multicompartimentales de ayuda al cumplimiento terapéutico (STD, DMA o CAD): Permeabilidad a la humedad de dispositivos termosellados. *Pharm Care Esp*; 5: 151-158.
- Wilder, BJ; Leppik, I; Hietpas, TJ; Cloyd, JC; Randinitis, EJ; Cook, J (2001). Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. *Neurology*; 57 (4): 582-9.
- Wilner, AN (2004). Therapeutic equivalency of generic antiepileptic drugs: results of a survey. *Epilepsy Behav*; 5 (6): 995-8.
- Wolf, P; May, T; Tiska, G; Schreiber, G (1992). Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. *Arzneimittelforschung*; 42 (3): 284-8.
- World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. (2004). *J Int Bioethique*; 15 (1): 124-9.
- Yacobi, A; Masson, E; Moros, D; Ganes, D; Lapointe, C; Abolfathi, Z, et al. (2000). Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. *J Clin Pharmacol*; 40 (8): 826-35.
- Yazdaniyan, M; Briggs, K; Jankovsky, C; Hawi, A (2004). The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. *Pharm Res*; 21 (2): 293-9.
- Young, WW; Suryanarayanan, R (1991). Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions. *J Pharm Sci*; 80 (5): 496-500.
- Yu, LX; Straughn, AB; Faustino, PJ; Yang, Y; Parekh, A; Ciavarella, AB, et al. (2004). The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. *Mol Pharm*; 1 (5): 357-62.
- Zapater, P; Horga, JF (1999). [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use]. *Rev Neurol*; 29 (12): 1235-46.
- Zuidema, J; van Ginneken, CA (1983). Clearance concept in salivary drug excretion. Part I: theory. *Pharm Acta Helv*; 58 (3): 88-93.